Search

Your search keyword '"Paschen, Steffen"' showing total 253 results
Start Over Author "Paschen, Steffen"
253 results on '"Paschen, Steffen"'

2. Head movement dynamics in dystonia: a multi-centre retrospective study using visual perceptive deep learning

Author

Peach, Robert, Friedrich, Maximilian, Fronemann, Lara, Muthuraman, Muthuraman, Schreglmann, Sebastian R., Zeller, Daniel, Schrader, Christoph, Krauss, Joachim K., Schnitzler, Alfons, Wittstock, Matthias, Helmers, Ann-Kristin, Paschen, Steffen, Kühn, Andrea, Skogseid, Inger Marie, Eisner, Wilhelm, Mueller, Joerg, Matthies, Cordula, Reich, Martin, Volkmann, Jens, and Ip, Chi Wang

Published
2024
Full Text
View/download PDF

3. The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Author

Greten, Stephan, Wegner, Florian, Jensen, Ida, Krey, Lea, Rogozinski, Sophia, Fehring, Meret, Heine, Johanne, Doll-Lee, Johanna, Pötter-Nerger, Monika, Zeitzschel, Molly, Hagena, Keno, Pedrosa, David J., Eggers, Carsten, Bürk, Katrin, Trenkwalder, Claudia, Claus, Inga, Warnecke, Tobias, Süß, Patrick, Winkler, Jürgen, Gruber, Doreen, Gandor, Florin, Berg, Daniela, Paschen, Steffen, Classen, Joseph, Pinkhardt, Elmar H., Kassubek, Jan, Jost, Wolfgang H., Tönges, Lars, Kühn, Andrea A., Schwarz, Johannes, Peters, Oliver, Dashti, Eman, Priller, Josef, Spruth, Eike J., Krause, Patricia, Spottke, Annika, Schneider, Anja, Beyle, Aline, Kimmich, Okka, Donix, Markus, Haussmann, Robert, Brandt, Moritz, Dinter, Elisabeth, Wiltfang, Jens, Schott, Björn H., Zerr, Inga, Bähr, Mathias, Buerger, Katharina, Janowitz, Daniel, Perneczky, Robert, Rauchmann, Boris-Stephan, Weidinger, Endy, Levin, Johannes, Katzdobler, Sabrina, Düzel, Emrah, Glanz, Wenzel, Teipel, Stefan, Kilimann, Ingo, Prudlo, Johannes, Gasser, Thomas, Brockmann, Kathrin, Hoffmann, Daniel C., Klockgether, Thomas, Krause, Olaf, Heck, Johannes, Höglinger, Günter U., and Klietz, Martin

Published
2024
Full Text
View/download PDF

6. The Progressive Supranuclear Palsy Clinical Deficits Scale

Author

Piot, Ines, Schweyer, Kerstin, Respondek, Gesine, Stamelou, Maria, Sckopke, Philipp, Schenk, Thomas, Goetz, Christopher G, Stebbins, Glenn T, Höglinger, Günter U, Gasser, Thomas, Hermann, Andreas, Höglinger, Günter, Höllerhage, Matthias, Kimmich, Okka, Klockgether, Thomas, Levin, Johannes, Machetanz, Gerrit, Osterrath, Antje, Palleis, Carla, Prudlo, Johannes, Spottke, Annika, Berg, Daniela, Bürk, Katrin, Claßen, Joseph, Eggers, Carsten, Greuel, Andrea, Grimm, Max‐Joseph, Hermann, Lennard, Iankova, Vassilena, Jahn, Klaus, Jost, Wolfgang, Klietz, Martin, Kühn, Andrea, Marxreiter, Franz, Paschen, Steffen, Poetter‐Nerger, Monika, Preisl, Marie‐Therese, Prilop, Lisa, Tönges, Lars, Trenkwalder, Claudia, Warnecke, Tobias, Wegner, Florian, Winkler, Jürgen, Antonini, Angelo, P, Kailash P, L, Adam L, Colosimo, Carlo, Compta, Yaroslau, Corvol, Jean‐Christophe, I, Lawrence I, E, Anthony E, Litvan, Irene, R, Huw R, Nilsson, Christer, and Pantelyat, Alexander

Subjects
Pediatric, Clinical Research, Perinatal Period - Conditions Originating in Perinatal Period, Neurosciences, Brain Disorders, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Neurological, Disease Progression, Female, Fingers, Humans, Male, Motor Skills, Reproducibility of Results, Supranuclear Palsy, Progressive, progressive supranuclear palsy, clinical rating scales, outcome measures, power calculation, DescribePSP study group, ProPSP study group, MDS-endorsed PSP study group, Clinical Sciences, Human Movement and Sports Sciences, Neurology & Neurosurgery
Abstract

BackgroundThere is currently no undisputed, validated, clinically meaningful measure for deficits in the broad spectrum of PSP phenotypes.ObjectiveTo develop a scale to monitor clinical deficits in patients with PSP across its broad phenotypes.MethodsThe Progressive Supranuclear Palsy Clinical Deficits Scale was conceptualized to cover seven clinical domains (Akinesia-rigidity, Bradyphrenia, Communication, Dysphagia, Eye movements, Finger dexterity, and Gait & balance), each scored from 0 to 3 (no, mild, moderate, or severe deficits). User guidelines were developed to standardize its application. Progressive Supranuclear Palsy Clinical Deficits Scale scores were collected in patients fulfilling the MDS-PSP diagnostic criteria in two independent, multicenter, observational studies, both cross-sectionally (exploratory DescribePSP cohort; confirmatory ProPSP cohort) and longitudinally (12-months' follow-up, both cohorts).ResultsCognitive pretesting demonstrated easy scale utility. In total, 164 patients were scored (70.4 ± 7.6 years; 62% males, 35% variant phenotypes). Mean Progressive Supranuclear Palsy Clinical Deficits Scale completion time was 4 minutes. The Progressive Supranuclear Palsy Clinical Deficits Scale total score correlated with existing scales (e.g., Progressive Supranuclear Palsy Rating Scale: R = 0.88; P

Published
2020

7. Genetic stratification of motor and QoL outcomes in Parkinson's disease in the EARLYSTIM study

Author

Weiss, Daniel, Landoulsi, Zied, May, Patrick, Sharma, Manu, Schüpbach, Michael, You, Hana, Corvol, Jean Christophe, Paschen, Steffen, Helmers, Ann-Kristin, Barbe, Michael, Fink, Gereon, Kühn, Andrea A., Courbon, Christine Brefel, Wojtecki, Lars, Damier, Philippe, Fraix, Valerie, Houeto, Jean-Luc, Regis, Jean, Sixel-Döring, Friederike, Pinsker, Marcus O., Thobois, Stephane, Gharabaghi, Alireza, Stoker, Valerie, Timmermann, Lars, Schnitzler, Alfons, Krack, Paul, Vidailhet, Marie, Deuschl, Günther, and Krüger, Rejko

Published
2022
Full Text
View/download PDF

9. A Short Progressive Supranuclear Palsy Quality of Life Scale.

Author

Jensen, Ida, Stiel, Stephanie, Bebermeier, Sarah, Schrag, Anette, Greten, Stephan, Doll‐Lee, Johanna, Wegner, Florian, Ye, Lan, Heine, Johanne, Krey, Lea, Höllerhage, Matthias, Süß, Patrick, Winkler, Jürgen, Berg, Daniela, Paschen, Steffen, Tönges, Lars, Gruber, Doreen, Gandor, Florin, Jost, Wolfgang H., and Kühn, Andrea A.

Abstract

Objective: The Progressive Supranuclear Palsy quality of life scale (PSP‐QoL) has been shown to be a useful tool for capturing health‐related quality of life of patients in "everyday life" and in progressive supranuclear palsy (PSP) research. However, at 45 items in length, the questionnaire can take a long time, exhausting PSP patients, in particular if cognitive impaired, which can have a negative impact on the assessment. The aim of this study was to establish a condensed version of the PSP‐QoL for research and routine clinical care. Methods: In this retrospective study, data originating from a German cohort of PSP patients was analyzed. Data from 245 PSP patients were included in this study. The short PSP‐QoL questionnaire was created using a two‐factor solution and item‐total and inter‐item correlations for mental and physical aspects of daily living of the PSP‐QoL followed by confirmatory factor analysis. Results: The final scale included 12 items representing mental (five items) and physical symptoms (seven items). The specified two‐factor model displayed an excellent fit in the confirmatory factor analysis. The short Progressive Supranuclear Palsy Quality of Life scale (PSP‐ShoQoL) correlated moderately with the PSP Rating Scale (r [243] = 0.514, P < 0.001) and Geriatric depression scale (r [231] = 0.548, P < 0.001). Sensitivity to change confirmed a significant decrease in QoL after 12 months. Discussion: In this study, we created a 12‐item PSP‐ShoQoL designed to "facilitate" daily clinical work that correlated strongly with the PSP‐QoL and was sensitive to change. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Prospective, Multicenter, International Registry of Deep Brain Stimulation for Dystonia: Sub-analysis of Cervical Dystonia Patients (P1-3.018)

Author

Albanese, Alberto, primary, Schnitzler, Alfons, additional, Kuehn, Andrea, additional, Arkadir, David, additional, Ledingham, David, additional, Pedrosa, David, additional, Newman, Edward, additional, Regidor, Ignacio, additional, Volkmann, Jens, additional, Rudas, Marcin, additional, Contarino, Maria Fiorella, additional, Sensi, Mariachiara, additional, Barbe, Michael, additional, Poetter-Nerger, Monika, additional, Kovacs, Norbert, additional, Lehrke, Ralph, additional, Huh, Ryoong, additional, Paschen, Steffen, additional, Mandat, Tomasz, additional, Tufo, Tommaso, additional, Visser-Vandewalle, Veerle, additional, Coenen, Volker, additional, Tai, Yen, additional, Chen, Lilly, additional, Goldberg, Edward, additional, and Krauss, Joachim, additional

Published
2024
Full Text
View/download PDF

11. Real-world Outcomes from a Prospective, Multicenter Deep Brain Stimulation Registry of Essential Tremor Patients (P3-3.004)

Author

Deuschl, Guenther, primary, Kovacs, Norbert, additional, Loret, Griet, additional, Barbe, Michael, additional, Il-Lee, Jung, additional, Clement, Frederi C., additional, Blazquez-Estrada, Marta, additional, Classen, Serge Jaumà, additional, Pedrosa, David, additional, Volkmann, Jens, additional, Oliveira, Ana, additional, Paschen, Steffen, additional, Schuurman, P.R., additional, Chen, Lilly, additional, and Goldberg, Edward, additional

Published
2024
Full Text
View/download PDF

12. Phenotypical differentiation of tremor using time series feature extraction and machine learning

Author

Haering, Verena, primary, Selzam, Veronika, additional, Martin-Rodriguez, Juan Francisco, additional, Schwingenschuh, Petra, additional, Tamas, Gertrud, additional, Raethjen, Jan, additional, Paschen, Steffen, additional, Goltz, Franziska, additional, Mulroy, Eoin, additional, Latorre, Anna, additional, Mir, Pablo, additional, Helmich, Rick, additional, Bhatia, Kailash P, additional, Volkmann, Jens, additional, Peach, Robert L, additional, and Schreglmann, Sebastian, additional

Published
2024
Full Text
View/download PDF

16. Deep brain stimulation of the subthalamic nucleus (STN) restores spatial reversal learning in patients with Parkinson’s disease

Author

Schneider, Isabel, primary, Schönfeld, Robby, additional, Hanert, Annika, additional, Philippen, Sarah, additional, Tödt, Inken, additional, Granert, Oliver, additional, Mehdorn, Maximilian, additional, Becktepe, Jos, additional, Deuschl, Günther, additional, Berg, Daniela, additional, Paschen, Steffen, additional, and Bartsch, Thorsten, additional

Published
2024
Full Text
View/download PDF

21. How to Use the New European Academy of Neurology/Movement Disorder Society European Section Guideline for Invasive Therapies in Parkinson's Disease.

Author

Brinker, Dana, Smilowska, Katarzyna, Paschen, Steffen, Antonini, Angelo, Moro, Elena, and Deuschl, Günther

Subjects
PARKINSON'S disease, MOVEMENT disorders, IMPULSE control disorders, MILD cognitive impairment, TREMOR, NEUROLOGY, ORAL drug administration
Abstract

Background: The decision to choose invasive treatments for Parkinson's disease (PD) is complex and needs careful consideration. Objectives: Although the recommendations of the European Academy of Neurology/Movement Disorder Society European Section guideline for invasive therapies of PD are useful, the different clinical profiles of people with PD who seek advice for possible invasive therapy need further attention. Methods and Results: Here we describe 8 clinical standard situations of people with PD unsatisfied with their current oral treatment where invasive therapies may be considered. These are PD patients presenting with the following symptoms: (1) severe motor fluctuations, (2) beginning of levodopa‐responsive fluctuations, severe tremor at (3) young or (4) advanced age, (5) impulse control disorders and related behavioral disorders, (6) hallucinations and psychosis, (7) minimal cognitive impairment or mild dementia, and (8) patients in need of palliative care. For some of these conditions, evidence at lower level or simple clinical considerations exist. Conclusions: There are no one‐fits‐all answers, but physician and patient should discuss each option carefully considering symptom profile, psychosocial context, availability of therapy alternatives, and many other factors. The current paper outlines our proposed approach to these circumstances. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease

Author

Pürner, Dominik, primary, Hormozi, Mohammad, additional, Weiß, Daniel, additional, Barbe, Michael T., additional, Jergas, Hannah, additional, Prell, Tino, additional, Gülke, Eileen, additional, Pötter-Nerger, Monika, additional, Falkenburger, Björn, additional, Klingelhöfer, Lisa, additional, Gutsmiedl, Pia K., additional, Haslinger, Bernhard, additional, Jochim, Angela M., additional, Wolff, Andreas, additional, Schröter, Nils, additional, Rijntjes, Michel, additional, van Riesen, Christoph, additional, Scheller, Ute, additional, Wolz, Martin, additional, Amouzandeh, Ali, additional, Ebersbach, Georg, additional, Gruber, Doreen, additional, Kohl, Zacharias, additional, Maetzler, Walter, additional, Paschen, Steffen, additional, Pérez-González, Pablo, additional, Rozanski, Verena, additional, Schwarz, Johannes, additional, Südmeyer, Martin, additional, Torka, Elisabeth, additional, Wesbuer, Simone, additional, Bornmann, Sarah, additional, Flöel, Agnes, additional, Ip, Chi Wang, additional, Krause, Patricia, additional, Kühn, Andrea A., additional, Csoti, Ilona, additional, Herting, Birgit, additional, van de Loo, Simone, additional, Basheer, Aniz Ahammed, additional, Liszka, Robert, additional, Jost, Wolfgang H., additional, Koschel, Jiri, additional, Haller, Bernhard, additional, and Lingor, Paul, additional

Published
2023
Full Text
View/download PDF

23. The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Author

Greten, Stephan, primary, Wegner, Florian, additional, Jensen, Ida, additional, Krey, Lea, additional, Rogozinski, Sophia, additional, Fehring, Meret, additional, Heine, Johanne, additional, Doll-Lee, Johanna, additional, Pötter-Nerger, Monika, additional, Zeitzschel, Molly, additional, Hagena, Keno, additional, Pedrosa, David J., additional, Eggers, Carsten, additional, Bürk, Katrin, additional, Trenkwalder, Claudia, additional, Claus, Inga, additional, Warnecke, Tobias, additional, Süß, Patrick, additional, Winkler, Jürgen, additional, Gruber, Doreen, additional, Gandor, Florin, additional, Berg, Daniela, additional, Paschen, Steffen, additional, Classen, Joseph, additional, Pinkhardt, Elmar H., additional, Kassubek, Jan, additional, Jost, Wolfgang H., additional, Tönges, Lars, additional, Kühn, Andrea A., additional, Schwarz, Johannes, additional, Peters, Oliver, additional, Dashti, Eman, additional, Priller, Josef, additional, Spruth, Eike J., additional, Krause, Patricia, additional, Spottke, Annika, additional, Schneider, Anja, additional, Beyle, Aline, additional, Kimmich, Okka, additional, Donix, Markus, additional, Haussmann, Robert, additional, Brandt, Moritz, additional, Dinter, Elisabeth, additional, Wiltfang, Jens, additional, Schott, Björn H., additional, Zerr, Inga, additional, Bähr, Mathias, additional, Buerger, Katharina, additional, Janowitz, Daniel, additional, Perneczky, Robert, additional, Rauchmann, Boris-Stephan, additional, Weidinger, Endy, additional, Levin, Johannes, additional, Katzdobler, Sabrina, additional, Düzel, Emrah, additional, Glanz, Wenzel, additional, Teipel, Stefan, additional, Kilimann, Ingo, additional, Prudlo, Johannes, additional, Gasser, Thomas, additional, Brockmann, Kathrin, additional, Hoffmann, Daniel C., additional, Klockgether, Thomas, additional, Krause, Olaf, additional, Heck, Johannes, additional, Höglinger, Günter U., additional, and Klietz, Martin, additional

Published
2023
Full Text
View/download PDF

24. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial

Author

Negovanska, Velina, Welter, Marie-Laure, Corvol, Jean-Christophe, Agid, Yves, Navarro, Soledad, Meier, Niklaus, Hartmann, Andreas, Hesekamp, Helke, Cornu, Philippe, Möller, Bettina, Nebel, Adelheid, Raethjen, Jan, Knudsen, Karina, Volkmann, Jens, Falk, Daniela, Paschen, Steffen, Meister, Ingo, Kuhn, Jens, Donner, Kerstin, Kessler, Josef, Barbe, Michael, Fink, Gereon, Maarouf, Mohammad, Kühn, Andrea, Müller, Bianca, Faust, Katharina, Gruber, Doreen, Schneider, Gerd-H., Seigneuret, Eric, Pollak, Pierre, Fraix, Valerie, Kistner, Andrea, Rascol, Olivier, Arbus, Christophe, Danet, Lola, Chaynes, Patrick, Groiss, Stefan J., Hartmann, Christian, Südmeyer, Martin, Partowinia-Peters, Mahnaz, Vesper, Jan, Ledily, Severine, Damier, Philippe, Raoul, Sylvie, Trenkwalder, Claudia, Richter-Dreske, Wenke, Wächter, Tobias, Weiss, Daniel, Eusebio, Alexandro, Azulay, Jean Philippe, Polo, Gustavo, Pinto, Serge, Levin, Johannes, Dornier, Stephanie, Pene, Fredy, Hourton, Delphine, Quintin, Mathieu, Hoffart-Jourdain, Cecile, Brocvielle, Helene, Balthasar, Kerstin, Stein, Meryem, Harnisch, Susanne, Reuss, Alexander, Aminossadati, Behnaz, Nasemann, Christian, Oertel, Wolfgang, Bataille, Benoit, Hellwig, Dieter, Gharabaghi, Alireza, Amtage, Florian, Mertens, Patrick, Kloss, Manja, Post, Bart, Speelman, Hans, Lhommée, Eugénie, Wojtecki, Lars, Czernecki, Virginie, Witt, Karsten, Maier, Franziska, Tonder, Lisa, Timmermann, Lars, Hälbig, Thomas D, Pineau, Fanny, Durif, Franck, Witjas, Tatiana, Pinsker, Marcus, Mehdorn, Maximilian, Sixel-Döring, Friederike, Kupsch, Andreas, Krüger, Rejko, Elben, Saskia, Chabardès, Stephan, Thobois, Stéphane, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Regis, Jean-Marie, Maltête, David, Sauvaget, Anne, Rau, Jörn, Schnitzler, Alfons, Schüpbach, Michael, Schade-Brittinger, Carmen, Deuschl, Gunther, Houeto, Jean-Luc, and Krack, Paul

Published
2018
Full Text
View/download PDF

28. ID: 197707 Quality-of-Life Improvement and Patient's Impression of Change With Use of Directional DBS Therapy for PD

Author

Zesiewicz, Theresa, primary, Volkmann, Jens, additional, Barbe, Michael, additional, Paschen, Steffen, additional, Luca, Corneliu, additional, Zhao, Cong Zhi, additional, Ponce, Francisco, additional, Clement, Frederik, additional, Durphy, Jennifer, additional, Loret, Griet, additional, Prell, Tino, additional, Ostrem, Jill, additional, Siddiqui, Mustafa, additional, Tomycz, Nestor, additional, Pei, Yu, additional, and Jain, Roshini, additional

Published
2023
Full Text
View/download PDF

30. Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment – the ComOn-study

Author

Geritz, Johanna, Maetzold, Sara, Steffen, Maren, Pilotto, Andrea, Corrà, Marta F., Moscovich, Mariana, Rizzetti, Maria C., Borroni, Barbara, Padovani, Alessandro, Alpes, Annekathrin, Bang, Corinna, Barcellos, Igor, Baron, Ralf, Bartsch, Thorsten, Becktepe, Jos S., Berg, Daniela, Bergeest, Lu M., Bergmann, Philipp, Bouça-Machado, Raquel, Drey, Michael, Elshehabi, Morad, Farahmandi, Susan, Ferreira, Joaquim J., Franke, Andre, Friederich, Anja, Geisler, Corinna, Hüllemann, Philipp, Gierthmühlen, Janne, Granert, Oliver, Heinzel, Sebastian, Heller, Maren K., Hobert, Markus A., Hofmann, Marc, Jemlich, Björn, Kerkmann, Laura, Knüpfer, Stephanie, Krause, Katharina, Kress, Maximilian, Krupp, Sonja, Kudelka, Jennifer, Kuhlenbäumer, Gregor, Kurth, Roland, Leypoldt, Frank, Maetzler, Corina, Maia, Luis F., Moewius, Andreas, Neumann, Patricia, Niemann, Katharina, Ortlieb, Christian T., Paschen, Steffen, Pham, Minh H., Puehler, Thomas, Radloff, Franziska, Riedel, Christian, Rogalski, Marten, Sablowsky, Simone, Schanz, Elena M., Schebesta, Linda, Schicketmüller, Andreas, Studt, Simone, Thieves, Martina, Tönges, Lars, Ullrich, Sebastian, Urban, Peter P., Vila-Chã, Nuno, Wiegard, Anna, Warmerdam, Elke, Warnecke, Tobias, Weiss, Michael, Welzel, Julius, Hansen, Clint, and Maetzler, Walter

Published
2020
Full Text
View/download PDF

31. Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus.

Author

Debove, Ines, Paschen, Steffen, Amstutz, Deborah, Cardoso, Francisco, Corvol, Jean‐Christophe, Fung, Victor S.C., Lang, Anthony E., Martinez Martin, Pablo, Rodríguez‐Oroz, María C., Weintraub, Daniel, Krack, Paul, Deuschl, Günther, Sarfo, Fred Stephen, Akpalu, Albert Kwaku, Okubadejo, Njideka, Shalash, Ali Soliman, Hattori, Nobutaka, Lee, Jee‐Young, O'Sullivan, Sean, and Antonini, Angelo

Abstract

Background: Impulse‐control and related behavioral disorders (ICBDs) significantly impact the lives of Parkinson's disease (PD) patients and caregivers, with lasting consequences if undiagnosed and untreated. While ICBD pathophysiology and risk factors are well‐studied, a standardized severity definition and treatment evidence remain elusive. Objective: This work aimed to establish international expert consensus on ICBD treatment strategies. To comprehensively address diverse treatment availabilities, experts from various continents were included. Methods: From 2021 to 2023, global movement disorders specialists engaged in a Delphi process. A core expert group initiated surveys, involving a larger panel in three iterations, leading to refined severity definitions and treatment pathways. Results: Experts achieved consensus on defining ICBD severity, emphasizing regular PD patient screenings for early detection. General treatment recommendations focused on continuous monitoring, collaboration with significant others, and seeking specialist advice for legal or financial challenges. For mild to severe ICBDs, gradual reduction in dopamine agonists was endorsed, followed by reductions in other PD medications. Second‐line treatment strategies included diverse approaches like reversing the last medication change, cognitive behavior therapy, subthalamic nucleus deep brain stimulation, and specific medications like quetiapine, clozapine, and antidepressants. The panel reached consensus on distinct treatment pathways for punding and dopamine dysregulation syndrome, formulating therapy recommendations. Comprehensive discussions addressed management strategies for the exacerbation of either motor or non‐motor symptoms following the proposed treatments. Conclusion: The consensus offers in‐depth insights into ICBD management, presenting clear severity criteria and expert consensus treatment recommendations. The study highlights the critical need for further research to enhance ICBD management. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Optimal deep brain stimulation connectivity to treat Holmes tremor

Author

Al-Fatly, Bassam, primary, Tödt, Inken, additional, Tischer, Martha, additional, Neimat, Joseph, additional, Hedera, Peter, additional, Wong, Joshua, additional, Okun, Michael, additional, Nowacki, Andreas, additional, Aziz, Tipu, additional, Prokop, Thomas, additional, Coenen, Volker, additional, Bargiotas, Panagiotis, additional, Lachenmayer, Lenard, additional, Helmers, Ann-Kristin, additional, Paschen, Steffen, additional, Kühn, Andrea, additional, Horn, Andreas, additional, Fox, Michael, additional, Becktepe, Jos, additional, and Deuschl, Günther, additional

Published
2023
Full Text
View/download PDF

35. Effect of Lower Limb vs. Abdominal Compression on Mobility in Orthostatic Hypotension: A Single-Blinded, Randomized, Controlled, Cross-Over Pilot Study in Parkinson’s Disease

Author

Paschen, Steffen, primary, Hansen, Clint, additional, Welzel, Julius, additional, Albrecht, Judith, additional, Atrsaei, Arash, additional, Aminian, Kamiar, additional, Zeuner, Kirsten E., additional, Romijnders, Robbin, additional, Warmerdam, Elke, additional, Urban, Paul Peter, additional, Berg, Daniela, additional, and Maetzler, Walter, additional

Published
2022
Full Text
View/download PDF

39. O132 / #543 REAL-WORLD DEEP BRAIN STIMULATION OUTCOMES USING SYSTEMS WITH DIRECTIONALITY AND MULTIPLE INDEPENDENT CURRENT CONTROL

Author

Zesiewicz, Theresa, primary, Barbe, Michael, additional, Paschen, Steffen, additional, Luca, Corneliu, additional, Zhao, Cong Zhi, additional, Ponce, Francisco, additional, Durphy, Jennifer, additional, Ostrem, Jill, additional, Tomycz, Nestor, additional, Prell, Tino, additional, Pei, Yu, additional, and Jain, Roshini, additional

Published
2022
Full Text
View/download PDF

40. Genetic stratification of motor and QoL outcomes in Parkinson's disease in the EARLYSTIM study

Author

Luxembourg Centre for Systems Biomedicine (LCSB): Bioinformatics Core (R. Schneider Group) [research center], Luxembourg Centre for Systems Biomedicine (LCSB): Clinical & Experimental Neuroscience (Krüger Group) [research center], Weiss, Daniel, Landoulsi, Zied, May, Patrick, Sharma, Manu, Schüpbach, Michael, You, Hana, Corvol, Jean Christophe, Paschen, Steffen, Helmers, Ann-Kristin, Barbe, Michael, Fink, Gereon, Kühn, Andrea A., Courbon, Christine Brefel, Wojtecki, Lars, Damier, Philippe, Fraix, Valerie, Houeto, Jean-Luc, Regis, Jean, Sixel-Döring, Friederike, Pinsker, Marcus O., Thobois, Stephane, Gharabaghi, Alireza, Stoker, Valerie, Timmermann, Lars, Schnitzler, Alfons, Krack, Paul, Vidailhet, Marie, Deuschl, Günther, Krüger, Rejko, Luxembourg Centre for Systems Biomedicine (LCSB): Bioinformatics Core (R. Schneider Group) [research center], Luxembourg Centre for Systems Biomedicine (LCSB): Clinical & Experimental Neuroscience (Krüger Group) [research center], Weiss, Daniel, Landoulsi, Zied, May, Patrick, Sharma, Manu, Schüpbach, Michael, You, Hana, Corvol, Jean Christophe, Paschen, Steffen, Helmers, Ann-Kristin, Barbe, Michael, Fink, Gereon, Kühn, Andrea A., Courbon, Christine Brefel, Wojtecki, Lars, Damier, Philippe, Fraix, Valerie, Houeto, Jean-Luc, Regis, Jean, Sixel-Döring, Friederike, Pinsker, Marcus O., Thobois, Stephane, Gharabaghi, Alireza, Stoker, Valerie, Timmermann, Lars, Schnitzler, Alfons, Krack, Paul, Vidailhet, Marie, Deuschl, Günther, and Krüger, Rejko

Abstract

Purpose The decision for subthalamic deep brain stimulation (STN-DBS) in Parkinson's disease (PD) relies on clinical predictors. Whether genetic variables could predict favourable or unfavourable decisions is under investigation. Objective First, we aimed to reproduce the previous observation that SNCA rs356220 was associated with favourable STN-DBS motor response. In additional exploratory analyses, we studied if other PD risk and progression variants from the latest GWAS are associated with therapeutic outcome. Further, we evaluated the predictive value of polygenic risk scores. Methods We comprehensively genotyped patients from the EarlyStim cohort using NeuroChip, and assessed the clinico-genetic associations with longitudinal outcome parameters. Results The SNCA rs356220 variant did not predict UPDRS III outcomes. However, it was associated with quality of life improvement in secondary analyses. Several polymorphisms from previously identified GWAS hits predicted motor or quality of life outcomes in DBS patients. Polygenic risk scores did not predict any outcome parameter. Conclusions Our findings support the hypothesis that different common genetic markers are associated with favourable quality of life outcomes of STN-DBS in PD. These findings can be the basis for further validation in larger and independent cohorts.

Published
2022

41. The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life

Author

Toedt, Inken, Al-Fatly, Bassam, Granert, Oliver, Kuehn, Andrea A., Krack, Paul, Rau, Joern, Timmermann, Lars, Schnitzler, Alfons, Paschen, Steffen, Helmers, Ann-Kristin, Hartmann, Andreas, Bardinet, Eric, Schuepbach, Michael, Barbe, Michael T., Dembek, Till A., Fraix, Valerie, Kuebler, Dorothee, Brefel-Courbon, Christine, Gharabaghi, Alireza, Wojtecki, Lars, Pinsker, Marcus O., Thobois, Stephane, Damier, Philippe, Witjas, Tatiana, Houeto, Jean-Luc, Schade-Brittinger, Carmen, Vidailhet, Marie, Horn, Andreas, Deuschl, Guenther, Toedt, Inken, Al-Fatly, Bassam, Granert, Oliver, Kuehn, Andrea A., Krack, Paul, Rau, Joern, Timmermann, Lars, Schnitzler, Alfons, Paschen, Steffen, Helmers, Ann-Kristin, Hartmann, Andreas, Bardinet, Eric, Schuepbach, Michael, Barbe, Michael T., Dembek, Till A., Fraix, Valerie, Kuebler, Dorothee, Brefel-Courbon, Christine, Gharabaghi, Alireza, Wojtecki, Lars, Pinsker, Marcus O., Thobois, Stephane, Damier, Philippe, Witjas, Tatiana, Houeto, Jean-Luc, Schade-Brittinger, Carmen, Vidailhet, Marie, Horn, Andreas, and Deuschl, Guenther

Abstract

Background: Subthalamic nucleus deep brain stimulation (STN-DBS) effectively treats motor symptoms and quality of life (QoL) of advanced and fluctuating early Parkinson's disease. Little is known about the relation between electrode position and changes in symptom control and ultimately QoL. Objectives: The relation between the stimulated part of the STN and clinical outcomes, including the motor score of the Unified Parkinson's Disease Rating Scale (UPDRS) and the quality-of-life questionnaire, was assessed in a subcohort of the EARLYSTIM study. Methods: Sixty-nine patients from the EARLYSTIM cohort who underwent DBS, with a comprehensive clinical characterization before and 24 months after surgery, were included. Intercorrelations of clinical outcome changes, correlation between the affected functional parts of the STN, and changes in clinical outcomes were investigated. We further calculated sweet spots for different clinical parameters. Results: Improvements in the UPDRS III and Parkinson's Disease Questionnaire (PDQ-39) correlated positively with the extent of the overlap with the sensorimotor STN. The sweet spots for the UPDRS III (x = 11.6, y = -13.1, z = -6.3) and the PDQ-39 differed (x = 14.8, y = -12.4, z = -4.3) similar to 3.8 mm. Conclusions: The main influence of DBS on QoL is likely mediated through the sensory-motor basal ganglia loop. The PDQ sweet spot is located in a posteroventral spatial location in the STN territory. For aspects of QoL, however, there was also evidence of improvement through stimulation of the other STN subnuclei. More research is necessary to customize the DBS target to individual symptoms of each patient. (C) 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Published
2022

43. Real-World Deep Brain Stimulation Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control (P2-11.003)

Author

Zesiewicz, Theresa, primary, Barbe, Michael, additional, Paschen, Steffen, additional, Luca, Corneliu, additional, Zhao, Cong Zhi, additional, Ponce, Francisco, additional, Durphy, Jennifer, additional, Ostrem, Jill, additional, Tomycz, Nestor, additional, Prell, Tino, additional, Siddiqui, Mustafa, additional, Chen, Lilly, additional, and Jain, Roshini, additional

Published
2022
Full Text
View/download PDF

45. Optimal deep brain stimulation sites and networks for cervical vs. generalized dystonia

Author

Horn, Andreas, primary, Reich, Martin M., additional, Ewert, Siobhan, additional, Li, Ningfei, additional, Al-Fatly, Bassam, additional, Lange, Florian, additional, Roothans, Jonas, additional, Oxenford, Simon, additional, Horn, Isabel, additional, Paschen, Steffen, additional, Runge, Joachim, additional, Wodarg, Fritz, additional, Witt, Karsten, additional, Nickl, Robert C., additional, Wittstock, Matthias, additional, Schneider, Gerd-Helge, additional, Mahlknecht, Philipp, additional, Poewe, Werner, additional, Eisner, Wilhelm, additional, Helmers, Ann-Kristin, additional, Matthies, Cordula, additional, Krauss, Joachim K., additional, Deuschl, Günther, additional, Volkmann, Jens, additional, and Kühn, Andrea A., additional

Published
2022
Full Text
View/download PDF

47. The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life

Author

Tödt, Inken, primary, Al‐Fatly, Bassam, additional, Granert, Oliver, additional, Kühn, Andrea A., additional, Krack, Paul, additional, Rau, Joern, additional, Timmermann, Lars, additional, Schnitzler, Alfons, additional, Paschen, Steffen, additional, Helmers, Ann‐Kristin, additional, Hartmann, Andreas, additional, Bardinet, Eric, additional, Schuepbach, Michael, additional, Barbe, Michael T., additional, Dembek, Till A., additional, Fraix, Valerie, additional, Kübler, Dorothee, additional, Brefel‐Courbon, Christine, additional, Gharabaghi, Alireza, additional, Wojtecki, Lars, additional, Pinsker, Marcus O., additional, Thobois, Stephane, additional, Damier, Philippe, additional, Witjas, Tatiana, additional, Houeto, Jean‐Luc, additional, Schade‐Brittinger, Carmen, additional, Vidailhet, Marie, additional, Horn, Andreas, additional, and Deuschl, Günther, additional

Published
2022
Full Text
View/download PDF

48. Results of a Randomized Clinical Trial of Speech After Early Neurostimulation in Parkinson's Disease.

Author

Pinto, Serge, Nebel, Adelheid, Rau, Jörn, Espesser, Robert, Maillochon, Pauline, Niebuhr, Oliver, Krack, Paul, Witjas, Tatiana, Ghio, Alain, Cuartero, Marie‐Charlotte, Timmermann, Lars, Schnitzler, Alfons, Hesekamp, Helke, Meier, Niklaus, Müllner, Julia, Hälbig, Thomas D., Möller, Bettina, Paschen, Steffen, Paschen, Laura, and Volkmann, Jens

Abstract

Background: The EARLYSTIM trial demonstrated for Parkinson's disease patients with early motor complications that deep brain stimulation of the subthalamic nucleus (STN‐DBS) and best medical treatment (BMT) was superior to BMT alone. Objective: This prospective, ancillary study on EARLYSTIM compared changes in blinded speech intelligibility assessment between STN‐DBS and BMT over 2 years, and secondary outcomes included non‐speech oral movements (maximum phonation time [MPT], oral diadochokinesis), physician‐ and patient‐reported assessments. Methods: STN‐DBS (n = 102) and BMT (n = 99) groups underwent assessments on/off medication at baseline and 24 months (in four conditions: on/off medication, ON/OFF stimulation—for STN‐DBS). Words and sentences were randomly presented to blinded listeners, and speech intelligibility rate was measured. Statistical analyses compared changes between the STN‐DBS and BMT groups from baseline to 24 months. Results: Over the 2‐year period, changes in speech intelligibility and MPT, as well as patient‐reported outcomes, were not different between groups, either off or on medication or OFF or ON stimulation, but most outcomes showed a nonsignificant trend toward worsening in both groups. Change in oral diadochokinesis was significantly different between STN‐DBS and BMT groups, on medication and OFF STN‐DBS, with patients in the STN‐DBS group performing slightly worse than patients under BMT only. A signal for clinical worsening with STN‐DBS was found for the individual speech item of the Unified Parkinson's Disease Rating Scale, Part III. Conclusion: At this early stage of the patients' disease, STN‐DBS did not result in a consistent deterioration in blinded speech intelligibility assessment and patient‐reported communication, as observed in studies of advanced Parkinson's Disease. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Proposed Mobility Assessments with Simultaneous Full-Body Inertial Measurement Units and Optical Motion Capture in Healthy Adults and Neurological Patients for Future Validation Studies: Study Protocol

Author

Warmerdam, Elke, Romijnders, Robbin, Geritz, Johanna, Elshehabi, Morad, Maetzler, Corina, Otto, Jan Carl, Reimer, Maren, Stuerner, Klarissa, Baron, Ralf, Paschen, Steffen, Beyer, Thorben, Dopcke, Denise, Eiken, Tobias, Ortmann, Hendrik, Peters, Falko, von der Recke, Felix, Riesen, Moritz, Rohwedder, Gothia, Schaade, Anna, Schumacher, Maike, Sondermann, Anton, Maetzler, Walter, and Hansen, Clint

Subjects
Chemical technology, wearable sensors, food and beverages, Parkinson Disease, balance, TP1-1185, movement analysis, gait, multiple sclerosis, stroke, Article, Biomechanical Phenomena, Motion, Wearable Electronic Devices, Activities of Daily Living, chronic low back pain, Parkinson’s disease, Humans, Algorithms, Aged
Abstract

Healthy adults and neurological patients show unique mobility patterns over the course of their lifespan and disease. Quantifying these mobility patterns could support diagnosing, tracking disease progression and measuring response to treatment. This quantification can be done with wearable technology, such as inertial measurement units (IMUs). Before IMUs can be used to quantify mobility, algorithms need to be developed and validated with age and disease-specific datasets. This study proposes a protocol for a dataset that can be used to develop and validate IMU-based mobility algorithms for healthy adults (18–60 years), healthy older adults (&gt, 60 years), and patients with Parkinson’s disease, multiple sclerosis, a symptomatic stroke and chronic low back pain. All participants will be measured simultaneously with IMUs and a 3D optical motion capture system while performing standardized mobility tasks and non-standardized activities of daily living. Specific clinical scales and questionnaires will be collected. This study aims at building the largest dataset for the development and validation of IMU-based mobility algorithms for healthy adults and neurological patients. It is anticipated to provide this dataset for further research use and collaboration, with the ultimate goal to bring IMU-based mobility algorithms as quickly as possible into clinical trials and clinical routine.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results